New combo attack on rare blood cancer shows promise in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Pathologically confirmed NK/T-cell lymphoma. * Relapsed or refractory disease after at least 1 prior asparaginase-based chemotherapy-containing regimen, with or without radiotherapy. * At least 1 measurable or evaluable lesion according to Lugano 2014 criteria. * ECOG performance status 0 to 2. * Life expectancy greater than 12 weeks. * Adequate hematologic, hepatic, renal, coagulation, and cardiac function. * Recovery from prior anti-cancer treatment-related toxicities to CTCAE grade 1 or baseline, except for specified stable irreversible toxicities allowed by the investigator. * Negative pregnancy test for women of childbearing potential. * Willingness to use effective contraception. * Written informed consent. Exclusion Criteria: * Prior treatment with any EZH1/2 or EZH2 inhibitor. * Allogeneic hematopoietic stem cell transplantation within 5 years before study treatment. * Autologous hematopoietic stem cell transplantation within 3 months before study treatment. * Requirement for high-dose systemic corticosteroids or other immunosuppressive therapy within 14 days before study treatment, except permitted local/inhaled or short-course use. * Cytotoxic chemotherapy not discontinued within 14 days before study treatment. * Systemic anti-cancer therapy or investigational therapy within 4 weeks before study treatment. * Major surgery within 4 weeks or radiotherapy within 90 days before study treatment. * Active infection, including active/latent tuberculosis, HIV infection, active hepatitis B or C with detectable viral nucleic acid, or other clinically significant active viral infection. * Uncontrolled cardiovascular disease. * Persistent unresolved toxicities greater than CTCAE grade 1 from prior therapy, except alopecia. * Gastrointestinal disorders or prior intestinal surgery that may impair oral drug absorption. * Pregnancy or breastfeeding. * Psychiatric illness or inability to provide informed consent. * Any other condition that, in the investigator's judgment, makes the patient unsuitable for the study.